Literature DB >> 6783963

Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin.

K W Rammohan, H F McFarland, D E McFarlin.   

Abstract

Although the events which predispose a host to measles virus persistence remain largely unknown, measles antibody has been shown to contribute to the production of a persistent infection by this virus both in vivo and in vitro. Thus, the addition of measles antibody to cells infected with measles virus promotes virus persistence. Latent measles infection occurs in newborn hamsters with maternally acquired antibody after inoculation with measles virus in the immediate neonatal period. A subacute encephalitis with measles virus persistence has been induced in weanling BALB/c mice that received antibody after virus inoculation and in measles-immune primates infected with a virus derived from a patient with subacute sclerosing panencephalitis. Measles virus consists of six polypeptides, and treatment of measles-infected cells with antibody has been shown to alter the pattern of their synthesis. As the antigenic specificity of the antibody responsible for these observations is not known, we decided to investigate the effects of monoclonal antibodies directed against the individual measles polypeptides. We report here that a monoclonal antibody directed against the virus haemagglutinin, unlike an antibody to the virus nucleocapsid protein, is able to induce a subacute encephalitis in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6783963     DOI: 10.1038/290588a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  25 in total

Review 1.  Measles virus, immune control, and persistence.

Authors:  Diane E Griffin; Wen-Hsuan Lin; Chien-Hsiung Pan
Journal:  FEMS Microbiol Rev       Date:  2012-03-13       Impact factor: 16.408

2.  Productive measles virus brain infection and apoptosis in CD46 transgenic mice.

Authors:  A Evlashev; E Moyse; H Valentin; O Azocar; M C Trescol-Biémont; J C Marie; C Rabourdin-Combe; B Horvat
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

4.  Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis.

Authors:  A Löve; R Rydbeck; G Utter; C Orvell; K Kristensson; E Norrby
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

5.  Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

Authors:  J S Wolinsky; M N Waxham; A C Server
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

6.  Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein.

Authors:  T M Varsanyi; B Morein; A Löve; E Norrby
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

7.  Multiple viral mutations rather than host factors cause defective measles virus gene expression in a subacute sclerosing panencephalitis cell line.

Authors:  R Cattaneo; A Schmid; M A Billeter; R D Sheppard; S A Udem
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

8.  Biosynthesis of measles virus hemagglutinin in persistently infected cells.

Authors:  W J Bellini; G D Silver; D E McFarlin
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

9.  Antibody-induced restriction of viral gene expression in measles encephalitis in rats.

Authors:  U G Liebert; S Schneider-Schaulies; K Baczko; V ter Meulen
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

10.  Antibodies to varicella-zoster virus modulate antigen distribution but fail to induce viral persistence in vitro.

Authors:  C Sadzot-Delvaux; P Marc; L Lebon; M P Merville-Louis; J Piette; B Rentier
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.